Effect of spironolactone on ventricular arrhythmias in patients with left ventricular systolic dysfunction and implantable cardioverter defibrillators.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 3860972)

Published in Indian Heart J on April 28, 2012

Authors

Abdul Wase1, Naga Garikipati, Omar Mufti, Zulfiqar Mirza, Aparna Innaparthy, Anwarul Kabir, Mohammed B Quraishi, Ronald Markert

Author Affiliations

1: Good Samaritan Heart and Vascular Hospital, Dayton, OH, USA. abdul.wase@wright.edu

Articles cited by this

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med (1996) 15.04

Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25

A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med (1999) 10.17

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med (1997) 10.02

2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol (2009) 7.38

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation (1991) 4.65

Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 4.12

Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation (2004) 2.81

Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J (2008) 2.37

Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation (2000) 2.15

Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med (1999) 1.85

Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J (2010) 1.30

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res (1997) 1.24

Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem (1994) 1.18

Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. J Renin Angiotensin Aldosterone Syst (2006) 1.04

Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. Am J Physiol Heart Circ Physiol (2010) 1.04

Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol (2000) 0.94

Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail (2007) 0.93

Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can J Cardiol (2009) 0.89

Aldosterone impairs baroreflex sensitivity in healthy adults. Am J Physiol Heart Circ Physiol (2006) 0.89

Aldosterone induces electrical remodeling independent of hypertension. Int J Cardiol (2011) 0.86

Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. Arch Cardiovasc Dis (2008) 0.82

The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. Clin Cardiol (2010) 0.82

Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. Heart Rhythm (2009) 0.81

Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. Eur J Heart Fail (2006) 0.80

Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators. Europace (2010) 0.79

Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy. Pacing Clin Electrophysiol (2010) 0.79

[Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy]. Kardiologiia (2008) 0.77